Hearings

The Role of Pharmacy Benefit Managers

Subcommittee on the Administrative State, Regulatory Reform, and Antitrust

Location: 2141 RHOB

The Role of Pharmacy Benefit Managers


Hearing: "The Role of Pharmacy Benefit Managers"

Subcommittee on the Administrative State, Regulatory Reform, and Antitrust (Committee on the Judiciary)

Wednesday, September 11, 2024 (2:00 PM)

2141 RHOB
Washington, D.C.

Support Documents

  • A report from Brookings titled, A brief look at current debates about pharmacy benefit managers, submitted for the Record by Mr. Correa of CA [PDF] Added 09/12/2024 at 11:01 AM
  • A letter from California Life Sciences and California Pharmacists Association to members of the California Congressional Delegation regarding PBM reforms, submitted for the Record by Mr. Correa of CA [PDF] Added 09/12/2024 at 11:01 AM
  • A report from Compass Lexecon titled, PBMs and Prescription Drug Distribution: An Economic Analysis of Criticisms Levied Against Pharmacy Benefit Managers, submitted for the Record by Mr. Correa of CA [PDF] Added 09/12/2024 at 11:01 AM
  • A report from Drug Channels Institute titled, The 2024 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers, submitted for the Record by Mr. Correa of CA [PDF] Added 09/12/2024 at 11:01 AM
  • An article from The New York Times titled, The Opaque Industry Secretly Inflating Prices for Prescription Drugs, submitted for the Record by Mr. Correa of CA [PDF] Added 09/12/2024 at 11:01 AM
  • A report from the Federal Trade Commission titled, Pharmacy Benefit Managers: The Powerful Middlemen Inflating Drug Costs and Squeezing Main Street Pharmacies, submitted for the Record by Mr. Correa of CA [PDF] Added 09/12/2024 at 11:01 AM
  • A letter dated June 5, 2024, from PhRMA to Assistant Attorney General Kanter, Secretary Becerra, and Chair Khan regarding the consolidation of the health care market, submitted for the Record by Mr. Correa of CA [PDF] Added 09/12/2024 at 11:01 AM
  • An article from the Wall Street Journal titled, Mail-Order Drugs Were Supposed to Keep Costs Down. Its Doing the Opposite., submitted for the Record by Mr. Correa of CA [PDF] Added 09/12/2024 at 11:01 AM
  • A statement of dissent dated July 9, 2024, from Commissioner Melissa Holyoak of the Federal Trade Commission in the matter of the Pharmacy Benefit Managers Report, submitted for the Record by Mr. Moran of TX [PDF] Added 09/12/2024 at 11:01 AM
  • A question for the record to all witnesses, submitted for the Record by Mr. Correa of CA [PDF] Added 09/20/2024 at 12:14 PM
  • Response to the question for the record from Dr. Mattingly [PDF] Added 09/23/2024 at 09:13 AM
  • Response to the question for the record from Dr. Van Nuys [PDF] Added 10/01/2024 at 03:27 PM
  • Response to the question for the record from Dr. LoSasso [PDF] Added 10/02/2024 at 02:14 PM
  • Response to the question for the record from Dr. Frank [PDF] Added 10/03/2024 at 01:40 PM

First Published: September 4, 2024 at 04:29 PM

Witnesses

Dr. Richard Frank
Director, Health Program, Brookings Institution

  • Frank Testimony [PDF]
  • Frank Truth in Testimony [PDF]
  • Frank Bio [PDF]

Dr. Anthony T. LoSasso
Professor and Chair, Department of Economics, DePaul University

  • LoSasso Testimony [PDF]
  • LoSasso Truth in Testimony [PDF]
  • LoSasso Bio [PDF]

Dr. T. Joseph Mattingly II
Associate Professor and Vice Chair of Research, College of Pharmacy, University of Utah

  • Mattingly Testimony [PDF]
  • Mattingly Truth in Testimony [PDF]
  • Mattingly Bio [PDF]

Dr. Karen Van Nuys
Executive Director, Value of Life Sciences Innovation, USC Schaeffer Center

  • Van Nuys Testimony [PDF]
  • Van Nuys Truth in Testimony [PDF]
  • Van Nuys Bio [PDF]